Healthcare / Medical Instruments & SuppliesShenzhen
$44.63
-0.16 (-0.36%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $127.0M · quality 71.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
44/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.6B
P/E
29.0x
↑EV/EBITDA
10.3x
↓ROE
7.4%
↑Gross Margin
52.9%
↑Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-6.4%
FCF CAGR
-34.7%
FCF margin
8.4%
FCF / Net income
0.43x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.16B · net income $225.7M · FCF $97.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.16B | $1.16B | $843.5M | $1.12B | $1.42B |
| Net Income | $225.7M | $225.7M | $155.4M | $297.3M | $380.3M |
| EBITDA | $288.6M | $288.6M | $200.9M | $354.8M | $444.3M |
| EPS | 2.54 | 2.54 | 1.74 | 3.32 | 5.36 |
| Gross Margin | 52.9% | 52.9% | 48.3% | 45.9% | 41.6% |
| Operating Margin | 20.8% | 20.8% | 14.5% | 25.7% | 28.8% |
| Net Margin | 19.5% | 19.5% | 18.4% | 26.5% | 26.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | 0.14 | 0.01 | 0.01 |
| Current Ratio | 10.81 | 10.81 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $97.9M | $97.9M | $138.2M | $127.0M | $351.5M |
| Returns | |||||
| ROE | 7.4% | 7.4% | 5.5% | 10.7% | 14.6% |
| Valuation | |||||
| P/E | 28.98 | 28.98 | 24.90 | 17.17 | 21.60 |
| EV/EBITDA | 10.32 | 10.32 | 18.65 | 12.58 | 17.73 |
| P/B | 1.31 | 1.31 | 1.37 | 1.84 | 3.15 |
| Growth & Yield | |||||
| Revenue Growth | 37.5% | 37.5% | -24.9% | -20.7% | — |
| EPS Growth | 46.0% | 46.0% | -47.6% | -38.1% | — |
| Dividend Yield | 1.5% | 1.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
16.0%
EPS terminal req.
$3.96
Spread vs growth
30.0%
5Y implied EPS CAGR
13.5%
EPS terminal req.
$4.79
Spread vs growth
32.4%
10Y implied EPS CAGR
11.8%
EPS terminal req.
$7.72
Spread vs growth
34.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-29.1%
Start / end P/E
36.9x → 17.6x
EPS bridge
1.74 → 2.54
Residual
-24.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.